Chiasma Inc

NASDAQ:CHMA   3:59:59 PM EDT
4.24
+0.25 (+6.27%)
Products, Regulatory

Chiasma Announces Positive Topline Results From The MPOWERED Phase 3 Clinical Trial

Published: 11/18/2020 12:17 GMT
Chiasma Inc (CHMA) - Chiasma Announces Positive Topline Results From the Mpowered™ Phase 3 Clinical Trial Comparing Mycapssa® (octreotide Capsules) to Long Acting Injectables for the Maintenance Treatment of Adults With Acromegaly.
Chiasma Inc - 91% of Patients on Mycapssa Maintained Igf-1 Response in 9-month Randomized, Controlled Phase of Non-inferiority Trial.
Chiasma Inc - Intends to Submit a Marketing Application for Mycapssa in Eu in Mid-2021.
Chiasma Inc - Mpowered Phase 3 Study Met Its Primary Non-inferiority Endpoint.